既往二尖瓣手术后行经导管主动脉瓣置换术:TVT注册研究结果
BACKGROUND: Due to perceived technical challenges, patients with previous surgical mitral valve repair or replacement (SMVR) have been excluded from most transcatheter aortic valve replacement (TAVR) trials.…
要点
- 既往SMVR患者TAVR术后30天死亡率和并发症与无SMVR者相似。
- 既往SMVR类型对30天或1年生存无影响,不应排除TAVR。
核心结论
- 既往SMVR患者接受TAVR的30天结局与无SMVR者相似,1年死亡率略高,早期瓣周漏未增加。
- 既往SMVR不应成为合适患者接受TAVR的排除标准。
研究设计与样本
- 回顾性分析STS/ACC TVT注册研究,比较1097例既往SMVR患者与46327例无SMVR患者。
- 患者于2011年11月至2015年9月在美国394个中心接受TAVR。
主要发现
- 既往SMVR组更年轻、女性更多,STS预测死亡风险更高(8.6% vs 6.8%,P < .001)。
- 30天死亡率(4.6% vs 5.5%,P = .293)、心肌梗死、卒中、再干预、新透析或再住院无差异。
- 出院时中/重度瓣周漏相似(5.8% vs 4.9%,P = .343)。
- 1年死亡率既往SMVR组略高(20% vs 17.5%,P = .087),校正后显著(HR 1.18,P = .043)。
- 既往SMVR类型(修复、生物瓣置换或机械瓣置换)对30天或1年生存无影响。
临床怎么用
- 对既往SMVR患者,TAVR可作为合适候选者的治疗选择,不必因手术史排除。
- 术前应评估STS预测风险,并告知患者1年死亡率可能略高。
局限性
- 回顾性注册研究设计,可能存在选择偏倚和未测量混杂。
- 仅纳入美国中心数据,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to perceived technical challenges, patients with previous surgical mitral valve repair or replacement (SMVR) have been excluded from most transcatheter aortic valve replacement (TAVR) trials. Our objective was to compare the 30-day and 1-year outcomes of TAVR for patients with and without prior SMVR. METHODS: In a retrospective review of The Society of Thoracic Surgeons (STS) and American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry, we compared 1097 patients with prior SMVR to 46,327 patients without prior SMVR who underwent TAVR between November 2011 and September 2015 at 394 US centers. Preoperative characteristics, procedural details, and clinical outcomes were analyzed. RESULTS: Patients with previous SMVR were younger, more often female, and had higher STS predicted risk of mortality (8.6% vs 6.8%, P < .001). However, there was no difference in 30-day mortality (4.6% vs 5.5%, P = .293), myocardial infarction, stroke, reintervention, new dialysis, or readmission. Moderate/severe paravalvular leak at discharge was also similar (5.8% vs 4.9%, P = .343). At 1 year, morbidity was similar with slightly higher mortality among patients with prior SMVR (20% vs 17.5%, P = .087) that was significant after adjustment (hazard ratio 1.18, P = .043). The type of prior SMVR (repair, bioprosthetic replacement, or mechanical replacement) had no impact on 30-day or 1-year survival. CONCLUSIONS: Patients with prior SMVR undergoing TAVR had similar 30-day outcomes, slightly higher 1-year mortality, and no increase in early paravalvular leak compared with patients who did not have previous SMVR. Prior SMVR should not preclude TAVR for appropriately selected patients.
引用
- Thourani VH, Kelly JJ, Cervantes DG, et al. Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results From the Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2019. PMID: 31655043. doi:10.1016/j.athoracsur.2019.08.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。